Inhalon Biopharma – Study For Inhaled COVID-19 Antibody Therapy
John Whelan, President, CEO and Director of Inhalon Biopharma, a start-up immunotherapy company developing an inhaled “muco-trapping” antibody platf...
5306 articles
John Whelan, President, CEO and Director of Inhalon Biopharma, a start-up immunotherapy company developing an inhaled “muco-trapping” antibody platf...
Kathryn Lang, VP of Outcomes and Evidence at Guardant Health discusses the recent data shared at the 2021 American Society of Clinical Oncology (ASCO) o...
Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive...
The COVID-19 pandemic changed how consumers access care and brought health care payers and providers together to better enable providers to care for pat...
Andrew Greenspan, Vice President of Immunology Medical Affairs at Janssen discusses recent data from the Phase 3b SEAVUE study, the first head-to-head s...
Tony Ezell, President, North America and Chief Marketing Officer of BD (Becton, Dickinson and Company), discusses how BD and USA Track & Field (USATF) a...
Amyloidosis is a serious health condition that often goes undiagnosed – leading to improper management and heavy symptom burden on patients and families.
America is addicted to...being addicted, and during the pandemic, COVID has accelerated the addictive mindset. Dr. Learn more on Health Professional Radio.
Enveric Biosciences recently announced that it has signed a definitive agreement to acquire MagicMed Industries, a pharmaceutical drug discovery and dev...
Ed Fairburn, artist and one of the millions who has lived with migraine, discusses his unique art form using maps as portraits to show the complexities ...